Foresee Pharmaceuticals (6576) Stock Overview
Operates as biopharmaceutical company in the United States, China, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
6576 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Foresee Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$80.10 |
| 52 Week High | NT$93.70 |
| 52 Week Low | NT$57.70 |
| Beta | 0.72 |
| 1 Month Change | -6.32% |
| 3 Month Change | 1.01% |
| 1 Year Change | -4.30% |
| 3 Year Change | -36.68% |
| 5 Year Change | -25.14% |
| Change since IPO | -27.51% |
Recent News & Updates
Shareholder Returns
| 6576 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -2.9% | -0.1% | 4.1% |
| 1Y | -4.3% | 0.9% | 50.7% |
Return vs Industry: 6576 underperformed the TW Pharmaceuticals industry which returned 0.9% over the past year.
Return vs Market: 6576 underperformed the TW Market which returned 50.7% over the past year.
Price Volatility
| 6576 volatility | |
|---|---|
| 6576 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in TW Market | 10.0% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6576 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6576's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Ben Chien | www.foreseepharma.com |
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases.
Foresee Pharmaceuticals Co., Ltd. Fundamentals Summary
| 6576 fundamental statistics | |
|---|---|
| Market cap | NT$12.62b |
| Earnings (TTM) | -NT$1.23b |
| Revenue (TTM) | NT$519.61m |
Is 6576 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6576 income statement (TTM) | |
|---|---|
| Revenue | NT$519.61m |
| Cost of Revenue | NT$138.75m |
| Gross Profit | NT$380.86m |
| Other Expenses | NT$1.61b |
| Earnings | -NT$1.23b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.78 |
| Gross Margin | 73.30% |
| Net Profit Margin | -235.89% |
| Debt/Equity Ratio | 32.4% |
How did 6576 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 23:36 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Foresee Pharmaceuticals Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |
| Jane Jiang | Yuanta Research |